Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
105.43% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
MSB · Oct 31, 2023
MESABI TRUST. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001558370-23-019801General Corporate
Evidence method
Yoy · gp.fundamentals.revenue
5681.78% · CORE · VALID
Evidence method
Level · gp.fundamentals.gross_margin
83.46% · CORE · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History29 statesSelf-history eligible
Oct 31, 20203/3 normalizedLevel 3Jan 31, 20213/3 normalizedLevel 3Apr 30, 20213/3 normalizedLevel 3Jul 31, 20213/3 normalizedLevel 3Oct 31, 20213/3 normalizedLevel 3Jan 31, 20223/3 normalizedLevel 3Apr 30, 20223/3 normalizedLevel 3Oct 31, 20223/3 normalizedLevel 3Jan 31, 20233/3 normalizedLevel 3Apr 30, 20233/3 normalizedLevel 3Oct 31, 20233/3 normalizedLevel 3Jan 31, 20243/3 normalizedLevel 3Apr 30, 20243/3 normalizedLevel 3Jul 31, 20243/3 normalizedLevel 3Oct 31, 20243/3 normalizedLevel 3Jan 31, 20253/3 normalizedLevel 3Apr 30, 20253/3 normalizedLevel 3Jul 31, 20253/3 normalizedLevel 3Oct 31, 20253/3 normalizedLevel 3Apr 30, 20263/3 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 47.00%
- Current
- 105.43%
- Delta
- 58.43%
- Previous
- 92.86%
- Current
- 83.46%
- Delta
- -9.41%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.